Evaluation of the Use of Oral Antidiabetic Drugs in Type 2 Diabetes Mellitus Patients at the Outpatient Installation of Azizah Metro Hospital
DOI:
https://doi.org/10.54445/pharmademica.v5i1.90
Abstract View:
0
PDF downloads:
0
Keywords:
drug use evaluation, type 2 diabetes mellitus, outpatientAbstract
Diabetes mellitus (DM) is a chronic metabolic disease characterized by elevated blood glucose levels (hyperglycemia). This condition arises due to impaired insulin production, the body's inability to effectively utilize insulin, or a combination of both. The rational use of antidiabetic drugs is crucial in managing blood glucose levels in diabetic patients. This study aimed to evaluate the use of oral antidiabetic drugs in patients with type 2 DM at the outpatient clinic of Azizah Metro Hospital. The research employed a descriptive design with retrospective data collection, using patient medical records from October to December 2024 as the data source. The sampling technique was total sampling, with a total of 80 patients as respondents. The majority of patients were female (77.5%), and the most prevalent age group was 56–65 years (48.75%). Most patients were on monotherapy (68.75%), with glimepiride being the most frequently prescribed drug (33.75%). The evaluation results showed that all patients (100%) met the criteria for appropriate drug use based on patient condition, indication, drug type, and dosage. In conclusion, the use of oral antidiabetic drugs in type 2 DM outpatients at Azizah Metro Hospital during the period of October–December 2024 has met the principles of rational therapy with an accuracy rate of 100%.
Downloads
References
Aguayo-Mazzucato, C. (2020). Functional changes in beta cells during ageing and senescence. Diabetologia, 63(10), 2022–2029. https://doi.org/10.1007/s00125-020-05185-6
American Diabetes Association. (2017). 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018. Diabetes Care, 41(Supplement_1), S13–S27. https://doi.org/10.2337/dc18-S002
Artini, K. S., Listyani, T. A., & Puspitasari, G. (2023). Rasionalitas Penggunaan Obat Antidiabetes Pada Pasien DM Tipe 2 Pasien Rawat Jalan Di RSUD Dr. Moewardi Surakarta. MEDFARM: Jurnal Farmasi dan Kesehatan, 12(1), 9–18. https://doi.org/10.48191/medfarm.v12i1.160
Gostoli, S., Raimondi, G., Popa, A. P., Giovannini, M., Benasi, G., & Rafanelli, C. (2024). Behavioral Lifestyle Interventions for Weight Loss in Overweight or Obese Patients with Type 2 Diabetes: A Systematic Review of the Literature. Current Obesity Reports, 13(2), 224–241. https://doi.org/10.1007/s13679-024-00552-5
Ikawati, Z., Adi Jaya, M. K., Rahmawati, F., & Yasin, N. M. (2024). Evaluation of Insulin and Sulfonylurea Types on Severe Hypoglycemia Event Among Ambulatory Type 2 Diabetes Mellitus Patients. A Case-Control Hospital-Based Study in Bali. Biomedical and Pharmacology Journal, 17(4), 2249–2257. https://doi.org/10.13005/bpj/3021
Kiss, Z., Rokszin, G., Abonyi‐Tóth, Z., Jermendy, G., Kempler, P., Barkai, L., & Wittmann, I. (2019). Young adult patients with type 1 diabetes have a higher risk of mortality than those of similar age with type 2 diabetes: A nationwide analysis in Hungary. Diabetes/Metabolism Research and Reviews, 35(8), e3190. https://doi.org/10.1002/dmrr.3190
Lorenzoni, V., Baccetti, F., Genovese, S., Torre, E., & Turchetti, G. (2017). Cost-consequence analysis of sitagliptin versus sulfonylureas as add-on therapy for the treatment of diabetic patients in Italy. ClinicoEconomics and Outcomes Research, Volume 9, 699–710. https://doi.org/10.2147/CEOR.S141477
Mohan, V., Saboo, B., Khader, J., Modi, K. D., Jindal, S., Wangnoo, S. K., & Amarnath, S. (2022). Position of Sulfonylureas in the Current ERA: Review of National and International Guidelines. Clinical Medicine Insights: Endocrinology and Diabetes, 15, 11795514221074663. https://doi.org/10.1177/11795514221074663
Oktora, S. I., & Butar Butar, D. (2022). Determinants of Diabetes Mellitus Prevalence in Indonesia. Jurnal Kesehatan Masyarakat, 18(2), 266–273. https://doi.org/10.15294/kemas.v18i2.31880
Perkumpulan Endokrinologi Indonesia (PERKENI). (2021). Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 dewasa di Indonesia—2021. https://pbperkeni.or.id/wp-content/uploads/2021/11/22-10-21-Website-Pedoman-Pengelolaan-dan-Pencegahan-DMT2-Ebook.pdf?
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C. N., Mbanya, J. C., Pavkov, M. E., Ramachandaran, A., Wild, S. H., James, S., Herman, W. H., Zhang, P., Bommer, C., Kuo, S., Boyko, E. J., & Magliano, D. J. (2022). IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Research and Clinical Practice, 183, 109119. https://doi.org/10.1016/j.diabres.2021.109119
Susilawati, E., Levita, J., Susilawati, Y., & Sumiwi, S. A. (2023). Review of the Case Reports on Metformin, Sulfonylurea, and Thiazolidinedione Therapies in Type 2 Diabetes Mellitus Patients. Medical Sciences, 11(3), 50. https://doi.org/10.3390/medsci11030050
Tudurí, E., Soriano, S., Almagro, L., Montanya, E., Alonso-Magdalena, P., Nadal, Á., & Quesada, I. (2022). The pancreatic β-cell in ageing: Implications in age-related diabetes. Ageing Research Reviews, 80, 101674. https://doi.org/10.1016/j.arr.2022.101674
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Pratiwi May Pamungkas, Rifkarosita Putri Ginaris , Alfina Nurrahman
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
.png)
